Are you sure the person responsible for validating the...

Are you sure the person responsible for validating the technology - Prof Gordon Parker - is a BPO shareholder, Foolscap?

I doubt Parker is a holder.

If he was, the trial could clearly not be seen to be "independent".

The fact that Parker's colleague, Dr Michael Player, has entered a consulting/COO role with BPO in return for a share package poses issues but both Player and Parker might argue that Black Dog researchers operate within "Chinese Walls".

Whatever, the annual meeting is to be held tomorrow morning.

We may get news on progress of the trial.

Shareholders will be asked to approve a change of name to Medibio Ltd.

If they do, the ticker BPO will may be replaced.

With burial of the name BioProspect and with it the ticker tag, the company may be able to
place past negatives to rest.

It - and we - could look forward to rejuvenation, with our tech endorsed by one of the world's
foremost depression research institutes, the redoubtable Black Dog.